These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37199158)

  • 1. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.
    Verma S; Dhingra NK; Bonaca MP; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Iwata T; Nordaby M; Brueckmann M; Pocock SJ; Packer M;
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1334-1337. PubMed ID: 37199158
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.
    Samsky MD; Hellkamp A; Hiatt WR; Fowkes FGR; Baumgartner I; Berger JS; Katona BG; Mahaffey KW; Norgren L; Blomster JI; Rockhold FW; DeVore AD; Patel MR; Jones WS
    J Am Heart Assoc; 2021 Jun; 10(12):e018684. PubMed ID: 34056910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study.
    Zareini B; Blanche P; D'Souza M; Elmegaard Malik M; Nørgaard CH; Selmer C; Gislason G; Kristensen SL; Køber L; Torp-Pedersen C; Schou M; Lamberts M
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006260. PubMed ID: 32571092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of peripheral arterial disease on patients with congestive heart failure.
    Keswani AN; White CJ
    Heart Fail Clin; 2014 Apr; 10(2):327-38. PubMed ID: 24656109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent link between peripheral artery disease and muscle wasting in patients with heart failure.
    Ohori K; Yano T; Katano S; Kouzu H; Inoue T; Takamura Y; Nagaoka R; Ishigo T; Koyama M; Nagano N; Fujito T; Nishikawa R; Miura T
    ESC Heart Fail; 2020 Oct; 7(5):3252-3256. PubMed ID: 33121215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAPA-HF study: Are the benefits uniform across non-diabetic subgroups.
    Pareek A; Rajput R; Kumar Chopra H; Dharmadhikari S
    Indian Heart J; 2020; 72(5):469-470. PubMed ID: 33189217
    [No Abstract]   [Full Text] [Related]  

  • 11. CABG better than PCI for smokers and those with diabetes, PAD, or heart failure.
    BMJ; 2013 Apr; 346():f2534. PubMed ID: 23616375
    [No Abstract]   [Full Text] [Related]  

  • 12. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
    Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Packer M
    Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study.
    Melgaard L; Gorst-Rasmussen A; Rasmussen LH; Lip GY; Larsen TB
    PLoS One; 2016; 11(3):e0152269. PubMed ID: 27015524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest.
    Patoulias D; Papadopoulos C; Katsimardou A; Doumas M
    Am J Cardiol; 2021 Jan; 139():134-136. PubMed ID: 33075281
    [No Abstract]   [Full Text] [Related]  

  • 18. Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control.
    Höbaus C; Herz CT; Wrba T; Koppensteiner R; Schernthaner GH
    Diab Vasc Dis Res; 2020; 17(2):1479164120914845. PubMed ID: 32308023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
    Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
    Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research digest: new horizons in heart failure therapy.
    Sattar N; Preiss D
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):832. PubMed ID: 31621593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.